01:50 PM EDT, 08/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target price by $2 to $58, valuing EQH shares at 7.1x our 2026 operating EPS estimate of $8.15 (raised by $0.40), versus the shares' one-year average forward multiple of 7x and a peer average of 8x. We lower our 2025 EPS estimate by $0.73 to $5.97. Q2 EPS of $1.10 versus $1.43 lagged our $1.75 EPS estimate and the $1.30 consensus view on adverse life mortality and lower fee revenues. Our upgrade reflects our view that EQH's July 31, 2025 life reinsurance deal will lower EQH's mortality exosyre by 75% and free up $2B in capital that EQH has been deploying into acquisitions and share buybacks. We view the shares as undervalued and see EQH's progress on 2027 goals of $2B in annual cash generation (2025 estimate is $1.6B-$1.7B) and 12% to 15% operating EPS growth, providing the shares (currently yielding 2%) with a catalyst to close their valuation gap to peers.